Effect of short-term levamisole therapy on delayed hypersensitivity
- 15 January 1980
- Vol. 45 (2) , 362-366
- https://doi.org/10.1002/1097-0142(19800115)45:2<362::aid-cncr2820450228>3.0.co;2-1
Abstract
A randomized trial of short-term Levamisole treatment was undertaken in a cancer population unresponsive to dinitrochlorobenzene (DNCB) to determine whether this agent increased delayed hypersensitivity. Of 100 patients entered, 50 received Levamisole (150 mg daily x 3) during DNCB challenge. The other 50 patients were challenged but not given the drug. The conversion rate to DNCB+ was 20% (10/50) for those treated and 12% (6/50) for controls. The difference is not significant. When all 100 patients were considered there was a statistically significant inverse relationship between extent of disease and the incidence of conversion to a DNCB reactive state. Levamisole as given does not appear to have a major influence on delayed cutaneous hypersensitivity.This publication has 8 references indexed in Scilit:
- Thymus-like activities of sulphur derivatives on T-cell differentiation.The Journal of Experimental Medicine, 1977
- Characterization of the immunostimulants levamisole and tetramisolePublished by Elsevier ,1975
- Sequential evaluation of general immune competence in cancer patients: Correlation with clinical courseCancer, 1975
- Restoration of host defense mechanisms in man by levamisoleLife Sciences, 1973
- 352. Note: Conservatism of the Approximation Σ(O - E) 2 /E in the Logrank Test for Survival Data or Tumor Incidence DataPublished by JSTOR ,1973
- Drug-Induced Restoration of Cutaneous Delayed Hypersensitivity in Anergic Patients with CancerNew England Journal of Medicine, 1973
- Impaired immunologic reactivity and recurrence following cancer surgeryCancer, 1970
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958